

REMARKS

I. Amendments to the Specification

The specification is amended herewith to correct typographical errors and to change the verb tense of portions of the Experimental section on pages 25-38 to consistently reflect those sections of the examples that are prophetic. The descriptions of Figures 4-6 on pages 6 and 30 have also been amended to reflect their prophetic nature. Through error and without deceptive intent, these portions of the specification that should have been written throughout in the present tense to reflect their prophetic nature were written in mixed present and past tense. The amendments correct the tense and are supported by the application as originally filed.

The descriptions of Figures 5 and 6 on page 6 have also been amended to indicate that an irrelevant antibody was used as a control for Figure 6. This sentence was inadvertently included in the description of Figure 5 instead of being properly included in the description of Figure 6. The proper description was included in the specification as originally filed in the title of Figure 6. Figures 1-10 have also been amended to delete the unnecessary titles.

The specification has also been amended at page 31 to add the reference which discloses the 1F5 antibody sequence. This sequence was included in the specification of the application as originally filed in Figure 7. Accordingly, no new matter is added by this Amendment and entry thereof is respectfully requested.

II. Amendment to the Claims

Claim 40-49 are canceled herewith and new claims 50 and 51 are presented for consideration. Support for new claims 50 and 51 can be found in the specification, for example, at pages 24-30. Accordingly, no new matter is added by this Amendment and entry thereof is respectfully requested.

III. Amendments to the Drawings

Herewith, Figures 1-10 are amended to omit the legend text following each figure number. As this information is presented in the specification under the heading "Detailed

Description of the Figures”, it need not be reiterated in the drawings themselves. Accordingly, no new matter is added by this Amendment and entry thereof is respectfully requested.

IV. Application Data Sheet

A Supplemental Application Data Sheet is submitted herewith to correct the inventor’s residence and update the inventor’s mailing address.

V. Information Disclosure Statement

A Supplemental Information Disclosure Statement in compliance with 37 C.F.R. § 1.97 is submitted herewith. Applicant respectfully requests consideration of the cited references.

VI. Provisional Rejection of Claims 40-49 for Obviousness-type Double-Patenting

Claims 40-49 stand provisionally rejected on the grounds of nonstatutory obviousness-type double-patenting as being unpatentable over claims 1-13 of co-pending Application No. 10/482,759. This rejection is rendered moot by Applicant’s cancellation of claims 40-49 in the present application and claims 1-13 of co-pending Application No. 10/482,759. Accordingly, Applicant respectfully requests that this rejection be reconsidered and withdrawn.

VII. Rejection of Claim 40 under 35 U.S.C. 112

Claim 40 stands finally rejected under 35 U.S.C. § 112, second paragraph, as being indefinite in its recitation of “the parent immunoglobulin.” This rejection is rendered moot by Applicant’s cancellation of claim 40. Accordingly, Applicant respectfully requests that this rejection be reconsidered and withdrawn.

VIII. Rejection of Claims 40-49 under 35 U.S.C. 102(b)

Claims 40-49 stand finally rejected under 35 U.S.C. § 102(b) as being anticipated by Queen et al. (U.S. Patent No. 5,693,762). This rejection is rendered moot by Applicant’s cancellation of claims 40-49. Furthermore, in that the Queen reference fails to disclose or suggest an immunoglobulin comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 47 and a light chain variable region having an amino acid sequence of

Applicant(s): Shawn Shui-on Leung
U.S. Serial No.: 09/892,613
Filed: June 27, 2001
Page: 7

SEQ ID NO: 48 as claimed, Applicant respectfully submits that it cannot anticipate the invention of claims 50 and 51. Accordingly, Applicant respectfully requests that this rejection be reconsidered and withdrawn.

IX. Conclusion

In view of the amendments and foregoing remarks, Applicant submits that the instant application is in condition for allowance. However, if the Examiner disagrees or should there be any questions, he is encouraged to contact the undersigned at the number listed below in order to expedite the prosecution of this application.

The outstanding Office Action set a three-month shortened statutory period for response. Accordingly, response is due on or before **August 9, 2007**. Thus, Applicant respectfully submits that this response is timely and that no additional fee is required. However, in the event that further fees are required to enter the instant response and/or maintain the pendency of this application, the Commissioner is authorized to charge such fees to the undersigned's Deposit Account No. **50-2101**.

Respectfully submitted,

Date: June 26, 2007

By: /chalin a. smith/

Smith Patent Consulting, LLC
3309 Duke Street
Alexandria, VA 22314

Name: Chalin A. Smith
Title: Attorney for Applicant
Registration No. 41,569

Telephone: (703) 549-7691
Facsimile: (703) 549-7692

CUSTOMER NUMBER 31,496